HR7050-119

What This Bill Does

The Homeopathic Drug Product Safety, Quality, and Transparency Act rewrites how federal drug law treats homeopathic drug products. It defines a homeopathic drug product as a drug with one or more homeopathic ingredients and no other active ingredient, and it defines homeopathic ingredients by reference to the Homeopathic Pharmacopoeia of the United States, State formularies, officially recognized homeopathic pharmacopoeias, or accredited voluntary consensus standards. New section 503E makes most of chapter V of the Federal Food, Drug, and Cosmetic Act inapplicable to homeopathic products except sections 501, 502, 510, and the new section itself. FDA rules, regulations, and guidance cannot conflict with section 503E or impose standards conflicting with recognized homeopathic standards. The bill deems products adulterated if they fail applicable homeopathic safety, quality, and manufacturing practices, allows alternative good manufacturing practice rules only when they do not conflict and receive advisory-committee support, creates a petition process for exemptions or variances, exempts finished products from active-ingredient identity and strength testing, and requires intermediate testing for risky undiluted substances. It permits retail labels to list supported self-limiting-condition indications with a disclaimer that the indications have not been evaluated by FDA, protects compliant claims from FTC and other substantiation requirements, bars private false-advertising actions based only on lack of clinical trials, requires homeopathic establishment registration and listing, bars FDA premarket approval, creates a 10-member Homeopathic Drug Product Advisory Committee with consumer, manufacturer, standards-body, physician, naturopath, pharmacist or chemist, veterinarian, FDA, and academic representation, and shifts enforcement through notice-and-cure, burden-of-proof, recall, seizure, injunction, and transition rules. Later sections amend supply-chain, nonprescription drug, and biologics definitions, withdraw FDA's 2022 homeopathic drug products guidance, and preserve the rest of the Act if one provision is invalidated.

Who Benefits and How

Homeopathic drug manufacturers, small homeopathic firms, homeopathic practitioners, naturopathic doctors, homeopathic pharmacists, veterinarians practicing homeopathy, the Homeopathic Pharmacopoeia Convention, accredited homeopathic standards bodies, and consumers who want continued access to homeopathic products benefit from a distinct pathway that removes premarket approval, limits conflicting FDA standards, recognizes homeopathic standards, and permits labeled indications with a disclaimer. Retail sellers benefit from clearer registration, listing, labeling, and marketing rules. Advisory-committee participants benefit from formal influence over FDA homeopathic drug policy.

Who Bears the Burden and How

FDA drug reviewers, FDA compliance officers, Federal Trade Commission advertising staff, State consumer protection enforcers, conventional drug manufacturers, clinical-evidence advocates, and consumers relying on FDA review bear risks or work created by the bill. FDA must adjust regulations, establishment listings, enforcement policies, recall strategy, and advisory-committee procedures while accepting notice-and-cure steps, higher proof burdens, and limits on premarket approval. Consumers may face greater responsibility for interpreting labels whose indications have not been evaluated by FDA. Conventional drug manufacturers may face competition from products that do not go through the same approval or substantiation pathway.

Key Provisions

• Defines homeopathic drug products and homeopathic ingredients under the Federal Food, Drug, and Cosmetic Act.
• Limits chapter V drug authorities for homeopathic products to new section 503E and sections 501, 502, and 510.
• Requires homeopathic products to follow recognized homeopathic safety, quality, manufacturing, and labeling standards.
• Exempts finished homeopathic products from active-ingredient identity and strength testing while retaining contaminant and defect testing.
• Allows labels to state supported self-limiting-condition indications with an FDA-not-evaluated disclaimer.
• Bars FDA premarket approval requirements for homeopathic drug products.
• Creates a Homeopathic Drug Product Advisory Committee with homeopathic consumer, manufacturer, standards, practitioner, FDA, and academic members.
• Restricts false-advertising and private-action claims when labels and marketing comply with the new homeopathic rules.
• Withdraws FDA's 2022 homeopathic drug products guidance and makes conforming amendments to supply-chain, nonprescription drug, and biologics definitions.